Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $5.2000 (-0.19%) ($5.2000 - $5.2000) on Thu. Jun. 17, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.66% (three month average) | RSI | 56 | Latest Price | $5.2000(-0.19%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS advances 0.2% a day on average for past five trading days. | Weekly Trend | ADMS declines -1% a week on average for past two weeks. | Market Behavior | Rotation from value to growth for large cap. Value stock sell-off for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) ACES(59%) ICLN(47%) IWC(29%) IWM(27%) IWN(26%) | Factors Impacting ADMS price | ADMS will decline at least -1.83% in a week (0% probabilities). IWF(-29%) GLD(-27%) XLU(-24%) VUG(-24%) XLP(-22%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -1.83% (StdDev 3.66%) | Hourly BBV | 0.3 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $5.12(1.56%) | 10 Day Moving Average | $5.07(2.56%) | 20 Day Moving Average | $5.13(1.36%) | To recent high | -11.4% | To recent low | 3.8% | Market Cap | $147m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |